MAIA Biotechnology, Inc.

05/20/2026

MAIA Biotechnology continues to advance its NSCLC clinical program across multiple development stages, including U.S. clinical site activation in THIO-101, ongoing Phase 2 survival follow-up, and funding visibility supporting the pivotal Phase 3 THIO-104 study.

These developments were also highlighted in a recent update from Diamond Equity Research, which reviews ongoing clinical and operational progress across the program.

Read more from Diamond Equity Research: https://bit.ly/4dCZt1U

05/18/2026

Diamond Equity Research released an updated research note on MAIA Biotechnology (NYSE: MAIA) highlighting recent clinical and operational progress across the company’s telomere-targeting immunotherapy programs.

The note includes updates on the ongoing THIO-101 Phase 2 expansion trial in advanced non-small cell lung cancer, including activation of the company’s first U.S. clinical site and plans for additional U.S. expansion during 2026.

Learn more: https://bit.ly/3RLkKyW Diamond Equity Research

04/27/2026

Approximately 50,000 patients in the U.S. progress to third-line non-small cell lung cancer (NSCLC), with many eventually progressing to later-line treatment settings where therapeutic options remain limited.

MAIA is advancing its THIO-101 clinical program to evaluate ateganosine, a telomere-targeting investigational therapy, in patients with advanced NSCLC who have progressed following prior lines of treatment.

The program continues to expand through ongoing global clinical activity and the activation of a U.S. clinical site.

Learn more: https://bit.ly/4sDCbOK

04/23/2026

MAIA has reported Phase 2 data from the THIO-101 study showing measures of efficacy that include disease control, response rates, and survival outcomes above historical standard-of-care benchmarks in a heavily pre-treated NSCLC population.

These results support continued clinical evaluation of ateganosine as the program advances, including the recent activation of a U.S. clinical site in the expansion study.

Learn more: https://bit.ly/4sDCbOK

04/20/2026

MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 expansion study, with additional U.S. sites planned in 2026.

The study is part of a broader global program evaluating ateganosine in advanced NSCLC, including ongoing activity across 44 sites in six countries.

The U.S. expansion marks a key milestone, broadening the patient pool for evaluation of ateganosine, a dual-mechanism therapy combining telomere targeting and immune activation.

More information: https://bit.ly/4sDCbOK

04/16/2026

Today, MAIA Biotechnology (NYSE: MAIA) announced the activation of its first U.S. clinical site for the ongoing Phase 2 THIO-101 trial expansion in non-small cell lung cancer (NSCLC).

The study is evaluating ateganosine, an investigational telomere-targeting therapy, in patients with advanced disease who have progressed after prior treatments. Additional U.S. sites are expected to be activated in 2026.

Learn more: https://bit.ly/4sDCbOK

04/14/2026

MAIA Biotechnology is advancing a differentiated approach in oncology by targeting the telomere biology that enables cancer cell immortality.

In an interview with BioTuesdays, CEO Vlad Vitoc, MA, MBA, discusses how ateganosine is designed to both induce cancer cell death and stimulate immune response, with early clinical data suggesting improvement in survival in pre-treated NSCLC patients.

Dive into the interview:

MAIA Biotechnology (NYSE American: MAIA) is focusing on the development and commercialization of breakthrough telomere-targeting immunotherapies: potential first-in-class drugs with novel mechanisms of action that aim to increase overall survival and improve the quality of life for patients with som...

04/08/2026

MAIA (NYSE: MAIA) expects recent $33 million capital raise to fully support its lead investigational therapy, ateganosine, as a treatment in non-small cell lung cancer.

The pivotal study, THIO-104, is currently evaluating ateganosine in sequence with a CPI in third-line NSCLC patients. Interim data is expected next year.

Read the press release: https://bit.ly/41TAhP3

04/07/2026

Coverage from Pharma Now highlights updated data from MAIA Biotechnology’s Phase 2 THIO-101 trial in NSCLC.

Eight patients treated with ateganosine followed by cemiplimab achieved survival beyond two years after prior checkpoint inhibitor therapy. The trial continues to evaluate this investigational sequencing approach, with ongoing patient follow-up and enrollment.

Learn more: https://bit.ly/3PKurwV

04/06/2026

MAIA Biotechnology presented updated Phase 2 THIO-101 clinical trial results at the European Lung Cancer Congress 2026.

Data from eight NSCLC patients treated with ateganosine sequenced with Libtayo showed survival exceeding two years, highlighting ongoing research in patients with relapsed disease.

Explore the full report from Noble Capital Markets (subscription required):

04/02/2026

New coverage in CURE Today highlights data from MAIA Biotechnology’s Phase 2 THIO-101 trial evaluating ateganosine sequenced with cemiplimab in patients with advanced .

Eight patients in the study achieved overall survival beyond two years following prior therapies, with ongoing monitoring for safety and long-term outcomes. The trial continues to assess both tolerability and clinical activity in this setting.

Learn more: https://bit.ly/4sclz0z